{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:35:54Z","timestamp":1790818554849,"version":"4.1.0"},"reference-count":30,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2005,2,1]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> Evaluate efficacy and toxicity of bortezomib in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> Patients were stratified, based on preclinical data, into arm A (mantle-cell lymphoma) or arm B (other B-cell lymphomas) without limitation in number of prior therapies. Bortezomib was administered as an intravenous push (1.5 mg\/m<jats:sup>2<\/jats:sup>) on days 1, 4, 8, and 11 every 21 days for a maximum of six cycles. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> Sixty patients with a median number of prior therapies of 3.5 (range, one to 12 therapies) were enrolled; 33 patients were in arm A and 27 were in arm B, including 12 diffuse large B-cell lymphomas, five follicular lymphomas (FL), three transformed FLs, four small lymphocytic lymphomas (SLL), two Waldenstr\u00f6m's macroglobulinemias (WM), and one marginal zone lymphoma. In arm A, 12 of 29 assessable patients responded (six complete responses [CR] and six partial responses [PR]) for an overall response rate (ORR) of 41% (95% CI, 24% to 61%), and a median time to progression not reached yet, with a median follow-up of 9.3 months (range, 1.7 to 24 months). In arm B, four of 21 assessable patients responded (one SLL patient had a CR, one FL patient had a CR unconfirmed, one diffuse large B-cell lymphoma patient had a PR, and one WM patient had a PR) for an ORR of 19% (95% CI, 5% to 42%). Grade 3 toxicity included thrombocytopenia (47%), gastrointestinal (20%), fatigue (13%), neutropenia (10%), and peripheral neuropathy (5%). Grade 4 toxicity occurred in nine patients (15%), and three deaths from progression of disease occurred within 30 days of withdrawal from study. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> Bortezomib showed promising activity in relapsed mantle-cell lymphoma and encouraging results in other B-cell lymphomas. Future studies will explore bortezomib in combination with other cytotoxic or biologic agents. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2005.03.108","type":"journal-article","created":{"date-parts":[[2004,12,22]],"date-time":"2004-12-22T03:00:17Z","timestamp":1103684417000},"page":"667-675","source":"Crossref","is-referenced-by-count":436,"title":["Phase II Study of Proteasome Inhibitor Bortezomib in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma"],"prefix":"10.1200","volume":"23","author":[{"given":"Andre","family":"Goy","sequence":"first","affiliation":[{"name":"From the Departments of Lymphoma and Myeloma, Molecular Pathology, Biostatistics, and Imaging, The University of Texas M.D. Anderson Cancer Center, Houston TX; Hematology Oncology Department, Hygeia Hospital, Athens, Greece; and Millennium Pharmaceuticals, Inc, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Younes","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma and Myeloma, Molecular Pathology, Biostatistics, and Imaging, The University of Texas M.D. Anderson Cancer Center, Houston TX; Hematology Oncology Department, Hygeia Hospital, Athens, Greece; and Millennium Pharmaceuticals, Inc, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"McLaughlin","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma and Myeloma, Molecular Pathology, Biostatistics, and Imaging, The University of Texas M.D. Anderson Cancer Center, Houston TX; Hematology Oncology Department, Hygeia Hospital, Athens, Greece; and Millennium Pharmaceuticals, Inc, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Pro","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma and Myeloma, Molecular Pathology, Biostatistics, and Imaging, The University of Texas M.D. Anderson Cancer Center, Houston TX; Hematology Oncology Department, Hygeia Hospital, Athens, Greece; and Millennium Pharmaceuticals, Inc, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge E.","family":"Romaguera","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma and Myeloma, Molecular Pathology, Biostatistics, and Imaging, The University of Texas M.D. Anderson Cancer Center, Houston TX; Hematology Oncology Department, Hygeia Hospital, Athens, Greece; and Millennium Pharmaceuticals, Inc, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick","family":"Hagemeister","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma and Myeloma, Molecular Pathology, Biostatistics, and Imaging, The University of Texas M.D. Anderson Cancer Center, Houston TX; Hematology Oncology Department, Hygeia Hospital, Athens, Greece; and Millennium Pharmaceuticals, Inc, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Fayad","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma and Myeloma, Molecular Pathology, Biostatistics, and Imaging, The University of Texas M.D. Anderson Cancer Center, Houston TX; Hematology Oncology Department, Hygeia Hospital, Athens, Greece; and Millennium Pharmaceuticals, Inc, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nam H.","family":"Dang","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma and Myeloma, Molecular Pathology, Biostatistics, and Imaging, The University of Texas M.D. Anderson Cancer Center, Houston TX; Hematology Oncology Department, Hygeia Hospital, Athens, Greece; and Millennium Pharmaceuticals, Inc, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Samaniego","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma and Myeloma, Molecular Pathology, Biostatistics, and Imaging, The University of Texas M.D. Anderson Cancer Center, Houston TX; Hematology Oncology Department, Hygeia Hospital, Athens, Greece; and Millennium Pharmaceuticals, Inc, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wang","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma and Myeloma, Molecular Pathology, Biostatistics, and Imaging, The University of Texas M.D. Anderson Cancer Center, Houston TX; Hematology Oncology Department, Hygeia Hospital, Athens, Greece; and Millennium Pharmaceuticals, Inc, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine","family":"Broglio","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma and Myeloma, Molecular Pathology, Biostatistics, and Imaging, The University of Texas M.D. Anderson Cancer Center, Houston TX; Hematology Oncology Department, Hygeia Hospital, Athens, Greece; and Millennium Pharmaceuticals, Inc, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Samuels","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma and Myeloma, Molecular Pathology, Biostatistics, and Imaging, The University of Texas M.D. Anderson Cancer Center, Houston TX; Hematology Oncology Department, Hygeia Hospital, Athens, Greece; and Millennium Pharmaceuticals, Inc, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Gilles","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma and Myeloma, Molecular Pathology, Biostatistics, and Imaging, The University of Texas M.D. Anderson Cancer Center, Houston TX; Hematology Oncology Department, Hygeia Hospital, Athens, Greece; and Millennium Pharmaceuticals, Inc, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas H.","family":"Sarris","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma and Myeloma, Molecular Pathology, Biostatistics, and Imaging, The University of Texas M.D. Anderson Cancer Center, Houston TX; Hematology Oncology Department, Hygeia Hospital, Athens, Greece; and Millennium Pharmaceuticals, Inc, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Hart","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma and Myeloma, Molecular Pathology, Biostatistics, and Imaging, The University of Texas M.D. Anderson Cancer Center, Houston TX; Hematology Oncology Department, Hygeia Hospital, Athens, Greece; and Millennium Pharmaceuticals, Inc, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Trehu","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma and Myeloma, Molecular Pathology, Biostatistics, and Imaging, The University of Texas M.D. Anderson Cancer Center, Houston TX; Hematology Oncology Department, Hygeia Hospital, Athens, Greece; and Millennium Pharmaceuticals, Inc, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Schenkein","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma and Myeloma, Molecular Pathology, Biostatistics, and Imaging, The University of Texas M.D. Anderson Cancer Center, Houston TX; Hematology Oncology Department, Hygeia Hospital, Athens, Greece; and Millennium Pharmaceuticals, Inc, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Cabanillas","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma and Myeloma, Molecular Pathology, Biostatistics, and Imaging, The University of Texas M.D. Anderson Cancer Center, Houston TX; Hematology Oncology Department, Hygeia Hospital, Athens, Greece; and Millennium Pharmaceuticals, Inc, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alma M.","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma and Myeloma, Molecular Pathology, Biostatistics, and Imaging, The University of Texas M.D. Anderson Cancer Center, Houston TX; Hematology Oncology Department, Hygeia Hospital, Athens, Greece; and Millennium Pharmaceuticals, Inc, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2003.n.025"},{"key":"R2","unstructured":"Coiffier B, Thieblemont C, Felman P, et al: Indolent nonfollicular lymphomas: Characteristics, treatment, and outcome. Semin Hematol 36:198,1999-208,"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(00)00255-2"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.5.1288"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.3109\/10428190009053541"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1007\/PL00002183"},{"key":"R7","unstructured":"Adams J, Palombella VJ, Sausville EA, et al: Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res 59:2615,1999-2622,"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1038\/nature02263"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-5002(03)00149-1"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.202445099"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-08-2543"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.8-6-508"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.1.88"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04438.x"},{"key":"R15","unstructured":"Pham L, Tamayo A, Lo P, et al: Anti-tumor activity of the proteasome inhibitor PS-341 in mantle cell lymphoma B cells. Blood 98:1945,2001,  (abstr 1945; suppl)"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.01.133"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030288"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05188.x"},{"key":"R19","unstructured":"Aghajanian C, Soignet S, Dizon DS, et al: A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 8:2505,2002-2511,"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2004.22.14_suppl.2108"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"R22","doi-asserted-by":"crossref","unstructured":"O'Connor OA, Wright J, Moskowitz C, et al: Phase II clinical experience with the proteasome inhibitor bortezomib (formerly PS-341) in patients with indolent lymphomas. Proc Am Soc Clin Oncol 22:566,2003,  (abstr 2277)","DOI":"10.1016\/S1359-6349(03)91036-6"},{"key":"R23","unstructured":"Assouline S, Belch A, Sehn L, et al: A phase II study of bortezomib in patients with mantle cell lymphoma. Blood 107:902a,2003,  (abstr 3358)"},{"key":"R24","doi-asserted-by":"crossref","unstructured":"O'Connor OA: Marked clinical activity of the novel proteasome inhibitor bortezomib in patients with relapsed follicular (RL) and mantle cell lymphoma (MCL). Proc Am Soc Clin Oncol 22:5785,2004,  (abstr 6582)","DOI":"10.1200\/jco.2004.22.90140.6582"},{"key":"R25","unstructured":"Ma MH, Yang HH, Parker K, et al: The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 9:1136,2003-1144,"},{"key":"R26","unstructured":"Cusack JC Jr, Liu R, Houston M, et al: Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-kappaB inhibition. Cancer Res 61:3535,2001-3540,"},{"key":"R27","unstructured":"Orlowski R, Hall M, Voorhees P, et al: Phase I study of the proteasome inhibitor bortezomib (PS-341, Velcade) in combination with pegylated liposomal doxorubicin (Doxil) in patients with refractory hematologic malignancies. Blood 100:105a,2002,  (abstr 388)"},{"key":"R28","unstructured":"Dunleavy KM, Janik J, Grant N, et al: Phase I\/II study of bortezomib combined with dose adjusted-EPOCH chemotherapy in relapsed or refractory diffuse large B-cell lymphomas. Blood 102:636a,2003,  (abstr 2349)"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-7372(03)00080-X"},{"key":"R30","unstructured":"Lonial S, Waller EK, Richardson PG, et al: Evaluation of the degree of thrombocytopenia and associated risk factors following bortezomib therapy for relapsed multiple myeloma. Blood 102:447a,2003,  (abstr 1632)"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2005.03.108","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:39:48Z","timestamp":1653511188000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2005.03.108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2,1]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,2,1]]}},"alternative-id":["10.1200\/JCO.2005.03.108"],"URL":"https:\/\/doi.org\/10.1200\/jco.2005.03.108","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,2,1]]}}}